Growth Metrics

Neogenomics (NEO) Total Current Liabilities (2016 - 2026)

Neogenomics filings provide 17 years of Total Current Liabilities readings, the most recent being $84.6 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 69.76% to $84.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $84.6 million, a 69.76% decrease, with the full-year FY2025 number at $88.3 million, down 70.69% from a year prior.
  • Total Current Liabilities hit $84.6 million in Q1 2026 for Neogenomics, down from $88.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $301.2 million in Q4 2024 to a low of $76.7 million in Q1 2024.
  • Median Total Current Liabilities over the past 5 years was $92.9 million (2023), compared with a mean of $136.8 million.
  • The widest YoY moves for Total Current Liabilities: up 264.61% in 2025, down 70.69% in 2025.
  • Neogenomics' Total Current Liabilities stood at $89.9 million in 2022, then grew by 7.09% to $96.3 million in 2023, then soared by 212.8% to $301.2 million in 2024, then plummeted by 70.69% to $88.3 million in 2025, then decreased by 4.2% to $84.6 million in 2026.
  • The last three reported values for Total Current Liabilities were $84.6 million (Q1 2026), $88.3 million (Q4 2025), and $97.9 million (Q3 2025) per Business Quant data.